Structural Heart Disease

The new scientific statement from the AHA indicates multiple social, economic, and health variables contribute to disparities in the development, diagnosis, and treatment of PAD.

On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.

An analysis of the Dubbo study suggests elevated Lp(a) is an independent and significant predictor of recurrent CHD in older people over a 16-year period.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

An analysis of 2 population-based cohorts suggests coronary artery calcium scores added to traditional risk-based models showed better discrimination than polygenic risk scores for CHD risk prediction.

A posthoc analysis of the EMPEROR-Preserved trial suggested empagliflozin decreased the risk of heart failure hospitalization or cardiovascular death, regardless of background diuretic status.

With ACC 2023 in the rearview, the HCPLive editorial team compiled perspectives on the meeting’s top piece of news from half a dozen clinicians specializing in various subspecialties across the spectrum of cardiovascular care.

In patients with acute coronary syndrome and multi-vessel heart disease, immediate stent treatment was as safe and effective as staged treatment at one year, according to late-breaking data presented at ACC 2023.

The statement suggests PCI without surgery on site is as safe as PCI at centers with on-site surgery across randomized controlled trials, observational studies, and international experiences.

An analysis of the Jackson Heart Study reports economic food insecurity as a risk factor for incident CHD and incident HFrEF, independent of socioeconomic measures and traditional CV risk factors.

Men in the highest quartile of PDE-5i exposure had the lowest incidence of MACE and overall mortality compared to the lowest exposure quartile.

An analysis of data from the STS Adult Cardiac Surgery Database provides an updated overview of the risks of mortality, morbidity, and conversion-to-replacement among patients undergoing mitral valve repair for primary mitral regurgitation.

The TAVI system Navitor from Abbott is designed to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.

An analysis of data from randomized clinical trials and non-randomized trials comparing TAVI and surgery provides an overview of 5-year incidence, outcomes, and predictors of structural valve deterioration with both approaches.

Released on Nov. 2, the 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease were created to be used concurrently with guidance published in 2020 and to replace previous guidance published in 2010 and 2015.

Data from the CLASP IID trial provide insight into the benefits of the PASCAL TEER system for degenerative mitral regurgitation, which demonstrated noninferiority to the MitraClip system for the trial's primary safety and efficacy endpoints.

Results of the PROTECTED TAVR trial suggest use of cerebral embolic protection devices was not associated with a reduction in risk of stroke within the first 72 hours after TAVR or prior to hospital discharge among patients with aortic stenosis.

Announced on September 15 by Edwards Lifesciences Corporation, the PASCAL Precision transcatheter valve repair system has received approval for transcatheter edge-to-edge repair in patients with degenerative mitral regurgitation.

A budget impact analysis details the benefits of TAVR compared with SAVR from the hospital payers' perspective among patients with low-risk aortic stenosis.

A new study provides insight into contemporary trends in gender- and income-based disparities in 30-day mortality risk following cardiac surgery among patients in the US.

An analysis of data from the PARTNERS trials and registries details associations between early LVEF improvement following TAVR and 5-year outcomes, including risk of all-cause and cardiovascular mortality.

A retrospective analysis of data from more than 480 LAAO procedures using the Watchman device provides insight into the benefits of preprocedural CT imaging compared to stand-alone TEE.

In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, are joined by special guest Anjali Owens, MD. An assistant professor of medicine and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens takes our hosts on a deep dive into the current state of management for oHCM and the impact of the US FDA's approval of mavacamten.

A new study from the Mayo Clinic provides insight into the prognostic value of mitral annulus calcification for predicting risk of mortality, regardless of whether or not patients had subsequent mitral valve dysfunction.

An analysis of data from the Cleveland Clinic Echocardiography database provides an overview of the association between the use of calcium supplements with increased risk of mortality and worsening stenosis among older patients with aortic stenosis.

A large-scale analysis of data from a pair of RCTs and a nonrandomized registry provide insight into the risk of valve deterioration seen with TAVR vs SAVR and to what extent this might influence risk of mortality.

ADAPT TAVR found use of edoxaban vs DAPT resulted in a numerical reduction in SLT, but this did not reach statistical significance and did not contribute to a reduction in stroke or cerebral lesions.

An analysis comparing 15-year outcomes following Ross procedure and biological or mechanical aortic valve replacement provides insight into the risk of mortality and other adverse outcomes associated with each procedure.

Announced on Dec. 20, the US FDA awarded approval to the Sapien 3 with Alterra from Edwards Lifesciences Corporation for pediatric and adult patients with severe pulmonary regurgitation.

Results of a recent study indicate each $1,000 decrease in median household income was associated with a 0.2% reduction in the number of TAVR procedures performed per 100,000 Medicare beneficiaries.